Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

NCT04189276 is registered in ClinicalTrials.gov with Tasly Tianjin Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04189276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
Lead sponsor
Tasly Tianjin Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
December 10, 2019
Completion date
December 31, 2021
Enrollment
100 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b virus (hbv)